MOBILE VIEW  | 

ESSENTIAL OILS

Classification   |    Detailed evidence-based information

Therapeutic Toxic Class

    A) Essential oils are heterogenic liquid mixtures of volatile and lipophilic compounds with distinct aromatic odors. They may be present in liniments, skin and sunburn analgesics, rubefacients, cold preparations, vaporizer solutions, and other alternative medicine preparations.
    B) The following agents have their own separate managements; please refer to them as indicated:
    1) Camphor
    2) Cinnamon oil
    3) Eucalyptus
    4) Peppermint oil
    5) Sandalwood oil
    6) Sassafras oil
    7) Thymol
    8) Turpentine oil

Specific Substances

    A) CONSTITUENTS OF THE GROUP
    1) Oil of allspice (synonym)
    2) Oil of amber (synonym)
    3) Oil of angelica (synonym)
    4) Oil of anise (synonym)
    5) Oil of anthemis (synonym)
    6) Oil of arbor vitae (synonym)
    7) Oil of asarum (synonym)
    8) Oil of balm (synonym)
    9) Oil of bay (synonym)
    10) Oil of bitter almond (synonym)
    11) Oil of bitter orange (synonym)
    12) Oil of cajeput (synonym)
    13) Oil of calemus (synonym)
    14) Oil of canada snakeroot (synonym)
    15) Oil of caraway (synonym)
    16) Oil of cardamon (synonym)
    17) Oil of cascarilla (synonym)
    18) Oil of cedar leaf (synonym)
    19) Oil of cedar wood (synonym)
    20) Oil of celery (synonym)
    21) Oil of chamomile (synonym)
    22) Oil of champaca (synonym)
    23) Oil of cherry laurel (synonym)
    24) Oil of citronella (synonym)
    25) Oil of copiaba (synonym)
    26) Oil of coriander (synonym)
    27) Oil of crispmint (synonym)
    28) Oil of cubeb (synonym)
    29) Oil of cumin (synonym)
    30) Oil of curled mint (synonym)
    31) Oil of cypress (synonym)
    32) Oil of dill (synonym)
    33) Oil of dwarf pine needles (synonym)
    34) Oil of East Indian geranuim (synonym)
    35) Oil of erigeron (synonym)
    36) Oil of fennel (synonym)
    37) Oil of fir (synonym)
    38) Oil of fir wood (synonym)
    39) Oil of fleabane (synonym)
    40) Oil of garlic (synonym)
    41) Oil of geranuim (synonym)
    42) Oil of ginger (synonym)
    43) Oil of hemlock (synonym)
    44) Oil of hops (synonym)
    45) Oil of horsemint (synonym)
    46) Oil of hyssop (synonym)
    47) Oil of indian grass (synonym)
    48) Oil of juniper (synonym)
    49) Oil of laurel (synonym)
    50) Oil of lavender (synonym)
    51) Oil of lemon (synonym)
    52) Oil of lemon myrtle (synonym)
    53) Oil of levant wormseed (synonym)
    54) Oil of linaloe (synonym)
    55) Oil of male fern (synonym)
    56) Oil of marjoram (synonym)
    57) Oil of matico (synonym)
    58) Oil of melissa (synonym)
    59) Oil of milfoid (synonym)
    60) Oil of monarda (synonym)
    61) Oil of mountain pine (synonym)
    62) Oil of myrica (synonym)
    63) Oil of myrtle (synonym)
    64) Oil of neroli (synonym)
    65) Oil of niaouli (synonym)
    66) Oil of orange (synonym)
    67) Oil of origanum (synonym)
    68) Oil of palmarosa (synonym)
    69) Oil of parsley (synonym)
    70) Oil of patchouli (synonym)
    71) Pogostemon cablin species
    72) Oil of pelargonium (synonym)
    73) Oil of pepper (synonym)
    74) Oil of pettitgrain (synonym)
    75) Oil of pimenta (synonym)
    76) Oil of pinus pumilio (synonym)
    77) Oil of rose geranium (synonym)
    78) Oil of rue (synonym)
    79) Oil of rusa (synonym)
    80) Oil of sandalwood (synonym)
    81) Oil of sage (synonym)
    82) Oil of savin (synonym)
    83) Oil of scotch fir (synonym)
    84) Oil of siberian fir (synonym)
    85) Oil of silver fir (synonym)
    86) Oil of silver pine (synonym)
    87) Oil of spearmint (synonym)
    88) Oil of spike (synonym)
    89) Oil of sweet bay (synonym)
    90) Oil of sweet flag (synonym)
    91) Oil of sweet orange (synonym)
    92) Oil of tansy (synonym)
    93) Oil of thuja (synonym)
    94) Oil of white cedar (synonym)
    95) Oil of wild marjoram (synonym)
    96) Oil of wormwood (synonym)
    97) Oil of yarrow (synonym)
    RELATED COMPOUNDS -- Volatile Oils
    1) Cedar leaf (synonym)
    2) Coriander oil (synonym)
    3) Lavandin extract (synonym)
    4) Lavandula species (synonym)
    5) Lavender (synonym)

Available Forms Sources

    A) SOURCES
    1) ANISE OIL (1% to 4%) is derived from pimpinella anisum. It has 80% to 90% anethole (Tabachi et al, 1974). Other ingredients include methyl chavicol, paramethoxyacetophenone (Anon, 1973) and myristicin (Harborne, 1969).
    2) PATCHOULI OIL is distilled from herbaceous leaves and is often used as a fragrance in aromatherapy. The more common species are pogostemon cablin (true patchouli), P. heyneanus, and P. hortensis ((Anon, 1997)).
    3) LAVENDER OIL is derived from the flower heads and foliage, with the most aromatic oil coming from the flower. The oil's main constituents are linalool, linalyl acetate, 1,8-cineole, beta-ocimene, terpinen-4-ol and camphor (Cavanagh & Wilkinson, 2002).
    4) LEMON MYRTLE OIL is native to Eastern Australia and predominantly contains citral (at least 85%) with two main isomeric aldehydes, neral and geranial (Hayes & Markovic, 2002; Hayes & Markovic, 2003).
    B) USES
    1) These combinations may be present in liniments, skin and sunburn analgesics, rubefacients, cold preparations, vaporizer solutions. Certain essential and volatile oils may be used alone as aromatherapy or herbal remedies for the relief of tooth aches, headaches, muscle aches, the common cold, and other problems. Certain essential and volatile oils are used in the food industry as flavorings and as perfumes (Budavari, 1996).
    2) Essential oils have been used as carminatives, expectorants, antipruritics, counterirritants, scabicides and insect repellants (Budavari, 1996).
    3) LAVANDULA species are used commercially in the fragrance industry in soaps, colognes, perfumes, skin lotions, and other cosmetics. It is also used in the food industry as a flavoring agent in beverages, ice cream, candy, baked goods and chewing gum (Landelle et al, 2008).

Life Support

    A) This overview assumes that basic life support measures have been instituted.

Clinical Effects

    0.2.1) SUMMARY OF EXPOSURE
    A) PHARMACOLOGY: The spasmodic activity of lavender oil is due primarily to one of its constituents, linalool. In vitro studies have shown that the mechanism of action was mediated through an intracellular rise in cAMP.
    B) TOXICOLOGY: Most essential oils cause mucous membrane irritation. aspiration is a risk from both the essential oil and from hydrocarbons or emulsifiers that are added to many preparations.
    C) EPIDEMIOLOGY: Exposures are common but serious toxicity is rare. Most serious effects are related to aspiration.
    D) WITH POISONING/EXPOSURE
    1) OVERDOSE: MILD TO MODERATE: There is little published information regarding the toxicity of the many essential oils. Expected effects include mucous membrane irritation or numbness, gastrointestinal irritation, dermal irritation, and hypersensitivity. Ocular exposure can cause irritation, considerable erythema, pain, chemical conjunctivitis, and in severe cases corneal scarring.
    2) SEVERE: Vertigo, ataxia, drowsiness, seizures, and coma can develop. Aspiration can cause severe pneumonitis. Rare, severe effects include respiratory depression, bradycardia, and hypotension.
    3) EUCALYPTOL: Severe metabolic acidosis and multi-organ system failure, including cardiovascular collapse, respiratory failure, and hepatic failure.
    4) FENNEL: Nausea, vomiting, seizure activity, pulmonary edema.
    5) GERANIUM: Allergic contact chelitis.
    6) LAVENDER: CNS depression, ataxia, photosensitizer that promotes hyperpigmentation, contact dermatitis.
    7) LEMON MYRTLE: Skin irritation and corrosion.
    8) THUJA (essential oil of the wormwood plant of the cedar family): Multiple tonic-clonic seizures.
    9) WORMWOOD: Acidosis, acute renal failure, respiratory acidosis, rhabdomyolysis, visual alterations, delirium, restlessness, paranoia, tremor, and seizures.
    0.2.20) REPRODUCTIVE
    A) Oil from Juniperus sabina when injected subcutaneously in pregnant mice induces resorptions. This oil is a well known abortifacient. Oil from Plectrantus fruticosus when given orally to pregnant rats induced resorptions and ocular malformations.

Laboratory Monitoring

    A) Blood or urine essential oil levels are not useful.
    B) Monitor vital signs and mental status. Monitor pulse oximetry and/or arterial blood gases and obtain a chest radiograph in patients with pulmonary signs or symptoms.
    C) Monitor fluid and electrolyte status in patients with severe vomiting and/or diarrhea.
    D) Monitor creatine kinase (CK) and renal function in patients with muscle soreness, or prolonged seizures or coma.
    E) Acute renal failure and rhabdomyolysis has been reported following ingestion of wormwood oil.

Treatment Overview

    0.4.2) ORAL/PARENTERAL EXPOSURE
    A) MANAGEMENT OF MILD TO MODERATE TOXICITY
    1) Treatment is symptomatic and supportive.
    B) MANAGEMENT OF SEVERE TOXICITY
    1) Monitor for CNS depression and respiratory depression or distress. Treat hypotension with IV fluids. Add vasopressors if hypotension persists. Treat seizures with benzodiazepines and barbiturates, or propofol if seizures persist or recur.
    C) DECONTAMINATION
    1) PREHOSPITAL: Gastrointestinal decontamination is not recommended because of the risk of aspiration. Remove contaminated clothing and wash exposed skin with soap and water. Irrigate exposed eyes.
    2) HOSPITAL: Gastrointestinal decontamination is not recommended because of the risk of aspiration. Remove contaminated clothing and wash exposed skin with soap and water. Irrigate exposed eyes.
    D) AIRWAY MANAGEMENT
    1) Patients with significant CNS or respiratory depression or aspiration may require endotracheal intubation and mechanical ventilation.
    E) ANTIDOTE
    1) None
    F) PULMONARY ASPIRATION
    1) Monitor ABGs and pulse oximetry, obtain chest radiograph.
    G) SEIZURE
    1) Treat seizures with benzodiazepines and barbiturates, or propofol if seizures persist or recur.
    H) HEPATOTOXICITY
    1) N-acetylcysteine (NAC) has been administered in cases of poisoning due to volatile oils, which have some similarities in bioactivation as acetaminophen (primarily pennyroyal and eugenol). The efficacy of NAC in treating hepatotoxicity from essential oil toxicity has not yet been established.
    I) ENHANCED ELIMINATION
    1) There is not strong evidence for the use of extracorporeal methods of elimination for volatile oils.
    J) PATIENT DISPOSITION
    1) HOME CRITERIA: Patients with small inadvertent exposures who have minimal symptoms (mild gastrointestinal upset or mucosal irritation) may be managed at home.
    2) OBSERVATION CRITERIA: Patients with more than mild symptoms and those with deliberate or large ingestions should be sent to a healthcare facility. patients who have remained asymptomatic for a period of 6 to 8 hours following an ingestion can be released from observation. Patients should be observed in a medical facility until free of symptoms.
    3) ADMISSION CRITERIA: All patients who have developed severe gastrointestinal, pulmonary, or neurologic effects of poisoning should be admitted.
    4) CONSULT CRITERIA: Consult a medical toxicologist for assistance with medical management in patients with severe toxicity or in whom the diagnosis is unclear.
    K) PITFALLS
    1) Failure to consider potential toxicity from other substances in preparations containing essential oils. Severe toxicity is not common, do not overtreat.
    L) TOXICOKINETICS
    1) Most essential oils are well absorbed through mucous membranes and many are well absorbed dermally. Excretion can occur via lungs, urine, feces, and skin. Essential oils are excreted unchanged or as hepatic metabolites. CNS effects generally occur within 30 minutes to 4 hours of exposure.
    M) DIFFERENTIAL DIAGNOSIS
    1) Exposure to solvents or hydrocarbons

Range Of Toxicity

    A) Toxic exposure varies with specific oil. Concentration of most volatile oils ranges from 10% to 20%.
    B) In commercial products, it has been estimated that essential oil concentrations may range from 1% to 20%, and that doses of 5 mL to 15 mL may be considered a potentially toxic exposure.
    C) WORMWOOD OIL: Clinical toxicity has occurred after 10 mL of oil of wormwood was ingested resulting in seizures, acidosis, acute renal failure, and rhabdomyolysis.

Summary Of Exposure

    A) PHARMACOLOGY: The spasmodic activity of lavender oil is due primarily to one of its constituents, linalool. In vitro studies have shown that the mechanism of action was mediated through an intracellular rise in cAMP.
    B) TOXICOLOGY: Most essential oils cause mucous membrane irritation. aspiration is a risk from both the essential oil and from hydrocarbons or emulsifiers that are added to many preparations.
    C) EPIDEMIOLOGY: Exposures are common but serious toxicity is rare. Most serious effects are related to aspiration.
    D) WITH POISONING/EXPOSURE
    1) OVERDOSE: MILD TO MODERATE: There is little published information regarding the toxicity of the many essential oils. Expected effects include mucous membrane irritation or numbness, gastrointestinal irritation, dermal irritation, and hypersensitivity. Ocular exposure can cause irritation, considerable erythema, pain, chemical conjunctivitis, and in severe cases corneal scarring.
    2) SEVERE: Vertigo, ataxia, drowsiness, seizures, and coma can develop. Aspiration can cause severe pneumonitis. Rare, severe effects include respiratory depression, bradycardia, and hypotension.
    3) EUCALYPTOL: Severe metabolic acidosis and multi-organ system failure, including cardiovascular collapse, respiratory failure, and hepatic failure.
    4) FENNEL: Nausea, vomiting, seizure activity, pulmonary edema.
    5) GERANIUM: Allergic contact chelitis.
    6) LAVENDER: CNS depression, ataxia, photosensitizer that promotes hyperpigmentation, contact dermatitis.
    7) LEMON MYRTLE: Skin irritation and corrosion.
    8) THUJA (essential oil of the wormwood plant of the cedar family): Multiple tonic-clonic seizures.
    9) WORMWOOD: Acidosis, acute renal failure, respiratory acidosis, rhabdomyolysis, visual alterations, delirium, restlessness, paranoia, tremor, and seizures.

Heent

    3.4.3) EYES
    A) WITH POISONING/EXPOSURE
    1) IRRITATION: These materials are all very irritating to the eye, producing considerable erythema and pain, but seldom any long term damage (Gurr & Scroggie, 1965).
    2) MENTHOL: Application to rabbit eyes has produced severe damage. Complete recovery was noted after application of 10 mg of menthol crystals (Grant & Schuman, 1993).
    3) OLBAS OIL: Corneal scarring has been reported following intranasal use.
    a) CASE REPORT: A 4-month-old boy developed chemical conjunctivitis and corneal scarring after intranasal instillation of several drops of Olbas oil (Wyllie & Alexander, 1994). Olbas oil is a mixture of oils of peppermint, clove, eucalyptus, menthol and cajub.
    4) OIL OF WORMWOOD: Chronic exposure to wormwood can result in visual alterations (Woolf, 1999).
    3.4.5) NOSE
    A) WITH POISONING/EXPOSURE
    1) CILIARY BEAT FREQUENCY (CBF): Lavender oil and thyme oil were found to increase CBF in vitro at a concentration of 0.2% and to a lesser extent, 2%. Disturbed CBF has been associated with rhinosinusitis, bronchitis and otitis media (Neher et al, 2008).
    3.4.6) THROAT
    A) WITH POISONING/EXPOSURE
    1) MUCOUS MEMBRANE IRRITATION: Essential oils are irritants, and commonly cause a burning sensation in the mouth, chest, and stomach after ingestion (Pilapil, 1989; Barkin et al, 1984).

Cardiovascular

    3.5.2) CLINICAL EFFECTS
    A) BRADYCARDIA
    1) WITH POISONING/EXPOSURE
    a) Bradycardia has been observed in some cases of acute exposure to mentha species (Woolf, 1999).
    B) CARDIOVASCULAR FINDING
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: Cardiovascular and respiratory collapse occurred within 2 days after ingesting approximately 3 Lof a mouthwash containing ethanol 27%, eucalyptol 0.092% (total amount ingested: 2.76 g), menthol 0.042% (total amount ingested: 1.26 g), thymol 0.064% (total amount ingested: 1.92 g), and methyl salicylate 0.060% (total amount ingested: 1.8 g). The patient developed severe metabolic acidosis, disseminated intravascular coagulation, anuria, hepatic failure, and hypoxemia despite aggressive supportive care, and subsequently died 48 hours after hospital admission (approximately 4 days post-ingestion). Although the primary ingredient within the mouthwash is ethanol, the authors believed that the severity and progression of his illness was primarily due to the large ingestion of volatile essential oils present in the mouthwash (total amount of eucalyptol, menthol, and thymol ingested: 5.94 g) (Soo Hoo et al, 2003).

Respiratory

    3.6.2) CLINICAL EFFECTS
    A) PULMONARY ASPIRATION
    1) WITH POISONING/EXPOSURE
    a) CITRONELLA OIL: In a review of 5 cases of citronella oil ingestion, aspiration pneumonitis developed in the only child treated with gastric lavage (uncuffed endotracheal tube in place during lavage) and in 1 of the 2 children in whom vomiting was induced (Temple et al, 1991).
    B) PULMONARY EDEMA
    1) WITH POISONING/EXPOSURE
    a) FENNEL OIL: Oral ingestion may produce pulmonary edema (Anon, 1994).
    C) DYSPNEA
    1) WITH POISONING/EXPOSURE
    a) OLBAS OIL: A 4-month-old boy developed severe respiratory distress with hypoxia, cyanosis, tachypnea (80 to 90 breaths/minute) wheezing, inspiratory stridor and profuse oral and nasal secretions after intranasal instillation of several drops of Olbas oil (Wyllie & Alexander, 1994). Olbas oil is a mixture of oils of peppermint, clove, eucalyptus, menthol and cajub.
    D) RESPIRATORY FAILURE
    1) WITH POISONING/EXPOSURE
    a) CASE REPORT: Cardiovascular and respiratory collapse occurred within 2 days after ingesting approximately 3 L of a mouthwash containing ethanol 27%, eucalyptol 0.092% (total amount ingested: 2.76 g), menthol 0.042% (total amount ingested: 1.26 g), thymol 0.064% (total amount ingested: 1.92 g), and methyl salicylate 0.060% (total amount ingested: 1.8 g). The patient developed severe metabolic acidosis, disseminated intravascular coagulation, anuria, hepatic failure, and hypoxemia despite aggressive supportive care, and subsequently died 48 hours after hospital admission (approximately 4 days postingestion). Although the primary ingredient within the mouthwash was ethanol, the authors believed that the severity and progression of his illness was primarily due to the large ingestion of volatile essential oils present in the mouthwash (total amount of eucalyptol, menthol, and thymol ingested: 5.94 g) (Soo Hoo et al, 2003).

Neurologic

    3.7.2) CLINICAL EFFECTS
    A) CENTRAL NERVOUS SYSTEM DEFICIT
    1) WITH POISONING/EXPOSURE
    a) Effects may be extremely variable depending on the amount, type, and concentration of the essential oil. Vertigo, ataxia, drowsiness, and coma have been noted.
    b) ONSET: CNS depression may have a rapid onset and many cases have progressed to coma within 30 minutes, although onset may be delayed for up to 4 hours and depression may persist for up to 3 days. Dizziness, giddiness, and disorientation usually occur in the first 30 minutes as well.
    c) LAVENDER OIL: A 19-month-old boy developed ataxia after ingesting an unknown amount of lavender oil (Wilkinson, 1991).
    d) LAVANDIN EXTRACT: An 18-month-old boy developed deep drowsiness and CNS depression approximately 3 hours after ingesting a small amount of lavandin extract. Upon presentation to the emergency department, motor responses were inducible only with painful stimulation, and the boy's breath had a distinctive lavender odor. The patient made a full recovery spontaneously in approximately 6 hours (Landelle et al, 2008).
    B) SEIZURE
    1) WITH POISONING/EXPOSURE
    a) Between 1976 and 1981, 8 cases of toxicity involving essential oils (sage, hyssop, thuja, and cedar leaves) resulting in seizure activity were reported to the Poison Control Center in Marseille, France. In 7 cases the essential oil was ingested for supposed therapeutic reasons; one case involved occupational exposure through pipetting. Recurrent seizures were observed in most cases. Neurologic investigation ruled out organic causes for the seizures in 6 cases but 2 patients had been on long-term anticonvulsant therapy. The seizure activity resolved spontaneously in 6 cases. In 2 cases, intensive respiratory care and anticonvulsant treatment was required (Millet et al, 1981).
    b) CEDAR LEAVES OIL
    1) A 32-year-old man developed seizures after ingesting 10 mL of cedar leaves oil to improve digestion. No residual complications were reported (Millet et al, 1981).
    c) FENNEL OIL
    1) FENNEL OIL: Oral exposure may produce seizures (Anon, 1994).
    d) HYSSOP OIL
    1) CASE REPORT: PEDIATRIC: A 6-year-old girl was medicated with hyssop oil, 2 to 3 drops/day by mouth to treat asthma. In addition, she was administered a single, 1/2 teaspoon dose infused in thyme for respiratory distress. The girl developed multiple seizures, metabolic acidosis, and required respiratory intensive care. She recovered after treatment (Millet et al, 1981).
    2) CASE REPORT: An 18-year-old woman developed seizures after ingesting 30 drops of hyssop oil to treat a cold. No residual complications were reported (Millet et al, 1981).
    3) CASE REPORT: A 26-year-old woman developed a tonic seizure on day 2 after ingesting hyssop oil 10 mL/day for 2 days to treat the flu. No residual complications were reported (Millet et al, 1981).
    e) OIL OF WORMWOOD
    1) Acute toxicity of wormwood poisoning includes seizures (Woolf, 1999).
    2) CASE REPORT: PEDIATRIC: A 7-month-old infant experienced a total of 8 tonic-clonic seizures in a 3-week period. The infant had been receiving thuja for 4 weeks as a calming agent around immunization times. All seizure activity ceased after stopping the thuja (derived from the WORMWOOD plant), and the child had no permanent neurologic or developmental complications (Stafstrom, 2007).
    3) CASE REPORT: A 31-year-old man ingested approximately 10 mL of essential oil of wormwood used in aromatherapy. Paramedics reported tonic-clonic seizures with decorticate posturing. There was no further seizure activity, and no focal neurologic abnormalities were reported (Weisbord et al, 1997).
    4) CASE REPORT: A 40-year-old woman developed seizure activity after ingesting 10 mL of thuja essential oil to enhance fitness. No residual complications were reported (Millet et al, 1981).
    5) CASE REPORT: A 50-year-old woman developed seizures 10 days after ingesting 25 drops/day of undiluted thuja oil, which was intended for dilution. During the seizure she sustained an occipito-parietal fracture. She recovered after treatment (Millet et al, 1981).
    f) SAGE OIL
    1) CASE REPORT: PEDIATRIC: A 33-day-old infant without risk for or history of seizure developed generalized tonic-clonic seizures 20 minutes after he was inadvertently exposed to an unreported amount of oral sage oil (Salvia officinalis). The seizure duration was 20 minutes. He presented to the emergency department after the seizure. Upon examination his heart rate was 120 beats/minute, rectal temperature 37.3 C, and respiratory rate 44 breaths/minute. Vertical nystagmus, irritability, and hyperreflexia were observed. He responded to treatment with rectal diazepam and was admitted for observation. He experienced a recurrent tonic-clonic seizure lasting about 1 minute 3 hours after admission and was treated with one dose of IV midazolam. He was discharged 3 days after admission and 1 year later remained seizure free (Halicioglu et al, 2011).
    2) CASE REPORT: PEDIATRIC: A 5-year-old girl without history of epilepsy developed a generalized tonic-clonic seizure lasting 10 minutes shortly after an inadvertent exposure to oral sage oil (amount undetermined). Upon presentation to the emergency department, she was treated with gastric lavage and active charcoal and then admitted to the pediatric intensive care unit. She did not develop recurrent seizures and was discharged in good health 48 hours after admission. One year later she remained seizure free (Halicioglu et al, 2011).
    C) CENTRAL NERVOUS SYSTEM FINDING
    1) WITH POISONING/EXPOSURE
    a) OIL OF WORMWOOD: Acute effects of wormwood poisoning may include symptoms of restlessness, delirium and paranoia (Woolf, 1999).
    b) CASE REPORT: A 31-year-old man accidentally ingested approximately 10 mL of oil of wormwood believing it was absinthe liqueur and several hours later was found in an agitated state, incoherent, and disoriented. Mental status improved with haloperidol. Lumbar puncture and head CT were within normal limits (Weisbord et al, 1997).
    D) CHRONIC POISONING
    1) WITH POISONING/EXPOSURE
    a) OIL OF WORMWOOD: Chronic exposure can lead to deteriorating mental status, seizures, tremors and coma (Woolf, 1999).

Gastrointestinal

    3.8.2) CLINICAL EFFECTS
    A) NAUSEA AND VOMITING
    1) WITH POISONING/EXPOSURE
    a) Heartburn, epigastric and oral pain, reflux, nausea, vomiting, and abdominal pain may occur shortly after ingestion (Antman et al, 1978; Craig, 1953; Pilapil, 1989; Perry et al, 1990; Grande & Dannewitz, 1987).
    b) EUCALYPTOL: CASE REPORT: Nausea, vomiting, and epigastric pain occurred in a 45-year-old man following ingestion of approximately 3 L of a mouthwash containing volatile essential oils, including eucalyptol (total amount ingested: 2.76 g), menthol (total amount ingested: 1.26 g), and thymol (total amount ingested: 1.92 g) (Soo Hoo et al, 2003).
    c) FENNEL OIL: Ingestion of the volatile oil can produce nausea and vomiting (Anon, 1994).
    d) OIL OF WORMWOOD: Vomiting is likely to occur following acute toxicity (Woolf, 1999).
    B) DIARRHEA
    1) WITH POISONING/EXPOSURE
    a) Diarrhea may occur. The fats, waxes, and oil could contribute to the diarrhea.
    C) CHRONIC POISONING
    1) WITH POISONING/EXPOSURE
    a) OIL OF WORMWOOD: Chronic exposure to the oil can result in gastritis and pica (Woolf, 1999).

Hepatic

    3.9.2) CLINICAL EFFECTS
    A) TOXIC LIVER DISEASE
    1) WITH POISONING/EXPOSURE
    a) COPAIBA: CASE REPORT: A 79-year-old woman who was taking Hypericum perforatum, copaiba, levothyroxine, omega 3, glucosamine and chondroitin, presented with a 1-month history of jaundice. On presentation, she was also tachycardic (100 beats/min) and laboratory results revealed elevated liver enzymes and hyperbilirubinemia. Following the discontinuation of all medications, except for levothyroxine, her laboratory results normalized (Agollo et al, 2014).

Genitourinary

    3.10.2) CLINICAL EFFECTS
    A) ACUTE RENAL FAILURE SYNDROME
    1) WITH POISONING/EXPOSURE
    a) OIL OF WORMWOOD: A 31-year-old man developed acute renal failure following an accidental ingestion of 10 mL of oil of wormwood. On day 3, the patient's serum creatinine peaked at 4.4 mg/dL. The patient was hydrated and given sodium bicarbonate; oliguria, hypocalcemia, or hypophosphatemia did not develop. By day 17, serum creatinine and electrolytes were within normal limits (Weisbord et al, 1997).
    B) NEPHRITIS
    1) WITH POISONING/EXPOSURE
    a) The essential oils are excreted in the urine. Irritation may rarely cause nephritis (Heng, 1987).

Acid-Base

    3.11.2) CLINICAL EFFECTS
    A) ACIDOSIS
    1) WITH POISONING/EXPOSURE
    a) OIL OF WORMWOOD: A 31-year-old man initially developed an anion gap metabolic and respiratory acidosis following a 10 mL ingestion of oil of wormwood. ABGs while receiving oxygen were: pH 7.27; PCO2, 43 mm Hg; and PO2 133 mm Hg, serum bicarbonate 7.7 mmol/L (Weisbord et al, 1997).
    b) CASE REPORT: A 45-year-old man presented to the ED with nausea, vomiting, lethargy, and hyperventilation 2 days after ingesting approximately 3 L of a mouthwash containing ethanol 27%, eucalyptol 0.092% (total amount ingested: 2.76 g), menthol 0.042% (total amount ingested: 1.26 g), thymol 0.064% (total amount ingested: 1.92 g), and methyl salicylate 0.060% (total amount ingested: 1.8 g). Arterial blood gases showed severe metabolic acidosis (pH 6.95, PaCO2 12 mmHg, PaO2 97 mmHg) with a calculated anion gap of 38 mmol/L. Hemodialysis resulted in initial correction of the patient's metabolic acidosis; however, he continued to deteriorate leading to respiratory and cardiovascular collapse and necessitating mechanical ventilation and vasopressor support. Progressive acidosis, hepatic failure, and hypoxemia ensued, despite aggressive supportive care, and the patient subsequently died 48 hours after hospital admission (approximately 4 days postingestion). Although ethanol is the primary ingredient in the mouthwash, the authors believed that the severity and progression of his illness was primarily due to the large ingestion of volatile essential oils present in the mouthwash (total amount of eucalyptol, menthol, and thymol ingested: 5.9 g) (Soo Hoo et al, 2003).

Dermatologic

    3.14.2) CLINICAL EFFECTS
    A) CONTACT URTICARIA
    1) WITH THERAPEUTIC USE
    a) SPEARMINT OIL (R-CARVONE): An adult reported a 6-month history of swelling of the lips a few minutes after contact with toothpaste, followed by gingival swelling and shortness of breath a short time later. He switched toothpaste brands several times with similar symptoms; an absence of symptoms was only observed with children's fruit-flavored toothpaste. Skin testing was strongly reactive with a wheal after 2 minutes with R-carvone (the main ingredient in spearmint oil) and S-carvone. No further symptoms were reported after the avoidance of spearmint gum or toothpaste. Cheilitis has been well documented with toothpaste containing carvone (Hansson et al, 2011)
    2) WITH POISONING/EXPOSURE
    a) These substances cause a redness and burning sensation of the skin (Spoerke et al, 1989). Although no actual burns usually result, skin irritation and urticaria have been noted with menthol-containing products (Parys, 1983).
    b) ANISE OIL: A 2% solution in a petrolatum base did not produce dermal reactions on human skin (Anon, 1994).
    1) Anethole (primary component of the oil) has caused sensitization which resulted in irritation, erythema, scaling, and vesication (Anon, 1973).
    2) When used in dental products, contact sensitivity has produced stomatitis and cheilitis (Duke, 1985).
    B) PHOTOSENSITIVITY
    1) WITH POISONING/EXPOSURE
    a) OIL OF LAVENDER: Lavender oil is a photosensitizer and may produce hyperpigmentation (Fisher, 1986).
    C) CONTACT DERMATITIS
    1) WITH THERAPEUTIC USE
    a) Contact dermatitis has been reported after chronic exposure to a number of essential oils including: lavender oil, sandalwood, lemon oil, eugenol, tea tree oil, chamomile oil, myrrh, frankincense, rosewood, geranium, vetiver, basil, marjoram, peppermint, sage, bergamot, orange, benzoin, ylang-ylang, laurel oil, pomerance flower oil, jasmine oil (Schaller & Korting, 1995; Selvaag et al, 1994; Selvaag et al, 1995; McGeorge & Steele, 1991; Sharma et al, 1987; Brandao, 1986).
    b) OIL OF LAVENDER: A 9 year study in Japan reported that 13.9% of exposures to lavender oil resulted in contact dermatitis (Cavanagh & Wilkinson, 2002).
    D) SKIN IRRITATION
    1) WITH POISONING/EXPOSURE
    a) LEMON MYRTLE OIL: Dermal exposure to neat lemon myrtle oil in vitro and subsequent absorption caused cellular necrosis (15%), vacuolation (25%) and loss of skin integrity. Similar effects, although to a lesser severity, were seen with a 1% lemon myrtle solution in vitro. The patho-histological skin alterations reported are indicative of skin irritation and corrosion (Hayes & Markovic, 2003).
    E) CHEILITIS
    1) WITH THERAPEUTIC USE
    a) GERANIUM OIL: Allergic contact cheilitis developed in an adult female following use of a lip balm product that contained geranium oil. Patch testing was positive, and gradual healing occurred after the product was stopped (Chang & Maibach, 1997).

Musculoskeletal

    3.15.2) CLINICAL EFFECTS
    A) RHABDOMYOLYSIS
    1) WITH POISONING/EXPOSURE
    a) OIL OF WORMWOOD: A 31-year-old man developed leg muscle soreness and a markedly elevated creatine kinase (serum CK greater than 80,000 Units/L) which peaked on day 3 of his hospital admission after oil of wormwood poisoning. Treatment consisted of sodium bicarbonate and saline. Further urine studies indicated a positive tetramethylbenzidine reaction suggestive of myoglobinuria; however, ammonium sulfate precipitation test was negative. By day 17, serum creatine kinase and other laboratory values were within normal limits (Weisbord et al, 1997).

Reproductive

    3.20.1) SUMMARY
    A) Oil from Juniperus sabina when injected subcutaneously in pregnant mice induces resorptions. This oil is a well known abortifacient. Oil from Plectrantus fruticosus when given orally to pregnant rats induced resorptions and ocular malformations.
    3.20.2) TERATOGENICITY
    A) ABORTION
    1) MICE - Oil from Juniperus sabina: when injected subcutaneously in pregnant mice, at doses of 15, 45 or 135 mg/kg it induces resorptions (Pages et al, 1989). This oil is a well known abortifacient (Banthrope et al, 1975; (Koedam & Looman, 1980; Schilcher, 1985). This oil is approximately 50% sabinyl acetate (Fournier et al, 1988).
    2) RATS - Oil from Plectrantus fruticosus: contains approximately 50% sabinyl acetate (Fournier et al, 1986a). When given orally to pregnant rats at doses of 5 or 20 mg/kg, it induced resorptions and ocular malformations (Pages et al, 1988; Fournier et al, 1986b; Pages et al, 1991; Dumitresco & Boudene, 1988).

Monitoring Parameters Levels

    4.1.1) SUMMARY
    A) Blood or urine essential oil levels are not useful.
    B) Monitor vital signs and mental status. Monitor pulse oximetry and/or arterial blood gases and obtain a chest radiograph in patients with pulmonary signs or symptoms.
    C) Monitor fluid and electrolyte status in patients with severe vomiting and/or diarrhea.
    D) Monitor creatine kinase (CK) and renal function in patients with muscle soreness, or prolonged seizures or coma.
    E) Acute renal failure and rhabdomyolysis has been reported following ingestion of wormwood oil.
    4.1.2) SERUM/BLOOD
    A) Although special laboratories may be able to quantify blood or urine essential oil levels, these have no clinical significance.
    B) Monitor fluid and electrolyte status in patients with severe vomiting and/or diarrhea.
    C) Acidosis, acute renal failure, and rhabdomyolysis have been reported in one case of oil of wormwood ingestion (Weisbord et al, 1997). Monitor creatine kinase (CK) and renal function in patients with muscle soreness, or prolonged seizures or coma.
    4.1.4) OTHER
    A) OTHER
    1) OTHER
    a) Monitor vital signs and mental status. Monitor pulse oximetry and/or arterial blood gases and obtain a chest radiograph in patients with pulmonary signs or symptoms.

Methods

    A) GAS CHROMATOGRAPHY/MASS SPECTROMETRY
    1) LAVANDIN EXTRACT: Blood and urine samples were examined using gas chromatography/mass spectrometry following an inadvertent exposure of lavandin in a child. Linalyl acetate, linalyl formate and acetone were identified in the samples and were the same components found in a sample of lavandin pure extract (Landelle et al, 2008).

Life Support

    A) Support respiratory and cardiovascular function.

Patient Disposition

    6.3.1) DISPOSITION/ORAL EXPOSURE
    6.3.1.1) ADMISSION CRITERIA/ORAL
    A) All patients who have developed severe gastrointestinal, pulmonary, or neurologic effects of poisoning should be admitted.
    6.3.1.2) HOME CRITERIA/ORAL
    A) Patients with small inadvertent exposures who have minimal symptoms (mild gastrointestinal upset or mucosal irritation) may be managed at home.
    6.3.1.3) CONSULT CRITERIA/ORAL
    A) Consult a medical toxicologist for assistance with medical management in patients with severe toxicity or in whom the diagnosis is unclear.
    6.3.1.5) OBSERVATION CRITERIA/ORAL
    A) Patients with more than mild symptoms and those with deliberate or large ingestions should be sent to a healthcare facility. patients who have remained asymptomatic for a period of 6 to 8 hours following an ingestion can be released from observation. Patients should be observed in a medical facility until free of symptoms.

Monitoring

    A) Blood or urine essential oil levels are not useful.
    B) Monitor vital signs and mental status. Monitor pulse oximetry and/or arterial blood gases and obtain a chest radiograph in patients with pulmonary signs or symptoms.
    C) Monitor fluid and electrolyte status in patients with severe vomiting and/or diarrhea.
    D) Monitor creatine kinase (CK) and renal function in patients with muscle soreness, or prolonged seizures or coma.
    E) Acute renal failure and rhabdomyolysis has been reported following ingestion of wormwood oil.

Oral Exposure

    6.5.1) PREVENTION OF ABSORPTION/PREHOSPITAL
    A) Prehospital decontamination is not recommended because of the risk of aspiration.
    6.5.2) PREVENTION OF ABSORPTION
    A) Gastrointestinal decontamination is not recommended because of the risk of aspiration.
    6.5.3) TREATMENT
    A) SUPPORT
    1) Treatment is symptomatic and supportive.
    B) MONITORING OF PATIENT
    1) Blood or urine essential oil levels are not useful.
    2) Monitor vital signs and mental status. Monitor pulse oximetry and/or arterial blood gases and obtain a chest radiograph in patients with pulmonary signs or symptoms.
    3) Monitor fluid and electrolyte status in patients with severe vomiting and/or diarrhea.
    4) Monitor creatine kinase (CK) and renal function in patients with muscle soreness, or prolonged seizures or coma.
    5) Acute renal failure and rhabdomyolysis has been reported following ingestion of wormwood oil.
    C) TOXIC LIVER DISEASE
    1) N-acetylcysteine (NAC) has been administered in other cases of poisoning due to volatile oils which have some similarities in bioactivation as acetaminophen (primarily pennyroyal and eugenol) (Mullen et al, 1994; Giorgi et al, 1994; Hartnoll et al, 1993). The efficacy of NAC in treating hepatotoxicity from essential oil toxicity has not yet been established.
    D) SEIZURE
    1) SUMMARY
    a) Attempt initial control with a benzodiazepine (eg, diazepam, lorazepam). If seizures persist or recur, administer phenobarbital or propofol.
    b) Monitor for respiratory depression, hypotension, and dysrhythmias. Endotracheal intubation should be performed in patients with persistent seizures.
    c) Evaluate for hypoxia, electrolyte disturbances, and hypoglycemia (or, if immediate bedside glucose testing is not available, treat with intravenous dextrose).
    2) DIAZEPAM
    a) ADULT DOSE: Initially 5 to 10 mg IV, OR 0.15 mg/kg IV up to 10 mg per dose up to a rate of 5 mg/minute; may be repeated every 5 to 20 minutes as needed (Brophy et al, 2012; Prod Info diazepam IM, IV injection, 2008; Manno, 2003).
    b) PEDIATRIC DOSE: 0.1 to 0.5 mg/kg IV over 2 to 5 minutes; up to a maximum of 10 mg/dose. May repeat dose every 5 to 10 minutes as needed (Loddenkemper & Goodkin, 2011; Hegenbarth & American Academy of Pediatrics Committee on Drugs, 2008).
    c) Monitor for hypotension, respiratory depression, and the need for endotracheal intubation. Consider a second agent if seizures persist or recur after repeated doses of diazepam .
    3) NO INTRAVENOUS ACCESS
    a) DIAZEPAM may be given rectally or intramuscularly (Manno, 2003). RECTAL DOSE: CHILD: Greater than 12 years: 0.2 mg/kg; 6 to 11 years: 0.3 mg/kg; 2 to 5 years: 0.5 mg/kg (Brophy et al, 2012).
    b) MIDAZOLAM has been used intramuscularly and intranasally, particularly in children when intravenous access has not been established. ADULT DOSE: 0.2 mg/kg IM, up to a maximum dose of 10 mg (Brophy et al, 2012). PEDIATRIC DOSE: INTRAMUSCULAR: 0.2 mg/kg IM, up to a maximum dose of 7 mg (Chamberlain et al, 1997) OR 10 mg IM (weight greater than 40 kg); 5 mg IM (weight 13 to 40 kg); INTRANASAL: 0.2 to 0.5 mg/kg up to a maximum of 10 mg/dose (Loddenkemper & Goodkin, 2011; Brophy et al, 2012). BUCCAL midazolam, 10 mg, has been used in adolescents and older children (5-years-old or more) to control seizures when intravenous access was not established (Scott et al, 1999).
    4) LORAZEPAM
    a) MAXIMUM RATE: The rate of intravenous administration of lorazepam should not exceed 2 mg/min (Brophy et al, 2012; Prod Info lorazepam IM, IV injection, 2008).
    b) ADULT DOSE: 2 to 4 mg IV initially; repeat every 5 to 10 minutes as needed, if seizures persist (Manno, 2003; Brophy et al, 2012).
    c) PEDIATRIC DOSE: 0.05 to 0.1 mg/kg IV over 2 to 5 minutes, up to a maximum of 4 mg/dose; may repeat in 5 to 15 minutes as needed, if seizures continue (Brophy et al, 2012; Loddenkemper & Goodkin, 2011; Hegenbarth & American Academy of Pediatrics Committee on Drugs, 2008; Sreenath et al, 2009; Chin et al, 2008).
    5) PHENOBARBITAL
    a) ADULT LOADING DOSE: 20 mg/kg IV at an infusion rate of 50 to 100 mg/minute IV. An additional 5 to 10 mg/kg dose may be given 10 minutes after loading infusion if seizures persist or recur (Brophy et al, 2012).
    b) Patients receiving high doses will require endotracheal intubation and may require vasopressor support (Brophy et al, 2012).
    c) PEDIATRIC LOADING DOSE: 20 mg/kg may be given as single or divided application (2 mg/kg/minute in children weighing less than 40 kg up to 100 mg/min in children weighing greater than 40 kg). A plasma concentration of about 20 mg/L will be achieved by this dose (Loddenkemper & Goodkin, 2011).
    d) REPEAT PEDIATRIC DOSE: Repeat doses of 5 to 20 mg/kg may be given every 15 to 20 minutes if seizures persist, with cardiorespiratory monitoring (Loddenkemper & Goodkin, 2011).
    e) MONITOR: For hypotension, respiratory depression, and the need for endotracheal intubation (Loddenkemper & Goodkin, 2011; Manno, 2003).
    f) SERUM CONCENTRATION MONITORING: Monitor serum concentrations over the next 12 to 24 hours. Therapeutic serum concentrations of phenobarbital range from 10 to 40 mcg/mL, although the optimal plasma concentration for some individuals may vary outside this range (Hvidberg & Dam, 1976; Choonara & Rane, 1990; AMA Department of Drugs, 1992).
    6) OTHER AGENTS
    a) If seizures persist after phenobarbital, propofol or pentobarbital infusion, or neuromuscular paralysis with general anesthesia (isoflurane) and continuous EEG monitoring should be considered (Manno, 2003). Other anticonvulsants can be considered (eg, valproate sodium, levetiracetam, lacosamide, topiramate) if seizures persist or recur; however, there is very little data regarding their use in toxin induced seizures, controlled trials are not available to define the optimal dosage ranges for these agents in status epilepticus (Brophy et al, 2012):
    1) VALPROATE SODIUM: ADULT DOSE: An initial dose of 20 to 40 mg/kg IV, at a rate of 3 to 6 mg/kg/minute; may give an additional dose of 20 mg/kg 10 minutes after loading infusion. PEDIATRIC DOSE: 1.5 to 3 mg/kg/minute (Brophy et al, 2012).
    2) LEVETIRACETAM: ADULT DOSE: 1000 to 3000 mg IV, at a rate of 2 to 5 mg/kg/min IV. PEDIATRIC DOSE: 20 to 60 mg/kg IV (Brophy et al, 2012; Loddenkemper & Goodkin, 2011).
    3) LACOSAMIDE: ADULT DOSE: 200 to 400 mg IV; 200 mg IV over 15 minutes (Brophy et al, 2012). PEDIATRIC DOSE: In one study, median starting doses of 1.3 mg/kg/day and maintenance doses of 4.7 mg/kg/day were used in children 8 years and older (Loddenkemper & Goodkin, 2011).
    4) TOPIRAMATE: ADULT DOSE: 200 to 400 mg nasogastric/orally OR 300 to 1600 mg/day orally divided in 2 to 4 times daily (Brophy et al, 2012).
    E) PULMONARY ASPIRATION
    1) If the patient is already coughing upon arrival, it is likely aspiration has already occurred. Monitor arterial blood gases in cases of severe aspiration pneumonitis to assure adequate ventilation.

Eye Exposure

    6.8.1) DECONTAMINATION
    A) EYE IRRIGATION, ROUTINE: Remove contact lenses and irrigate exposed eyes with copious amounts of room temperature 0.9% saline or water for at least 15 minutes. If irritation, pain, swelling, lacrimation, or photophobia persist after 15 minutes of irrigation, an ophthalmologic examination should be performed (Peate, 2007; Naradzay & Barish, 2006).
    B) These substances are strong eye irritants and will cause significant burning and redness. Because of their oily nature and waxy bases, it may take longer than normal periods of irrigation to remove them from the eye.
    C) Persistent inflammation or specific abnormalities may require an examination by a physician.

Dermal Exposure

    6.9.1) DECONTAMINATION
    A) DERMAL DECONTAMINATION
    1) DECONTAMINATION: Remove contaminated clothing and wash exposed area thoroughly with soap and water for 10 to 15 minutes. A physician may need to examine the area if irritation or pain persists (Burgess et al, 1999).
    6.9.2) TREATMENT
    A) SKIN ABSORPTION
    1) These materials may be absorbed via the skin, although the rates of absorption are variable. Chronic dermal use of these products may result in symptoms.
    B) Treatment should include recommendations listed in the ORAL EXPOSURE section when appropriate.

Enhanced Elimination

    A) LACK OF EFFECT
    1) There is not strong evidence for the use of extracorporeal methods of elimination for volatile oils.

Summary

    A) Toxic exposure varies with specific oil. Concentration of most volatile oils ranges from 10% to 20%.
    B) In commercial products, it has been estimated that essential oil concentrations may range from 1% to 20%, and that doses of 5 mL to 15 mL may be considered a potentially toxic exposure.
    C) WORMWOOD OIL: Clinical toxicity has occurred after 10 mL of oil of wormwood was ingested resulting in seizures, acidosis, acute renal failure, and rhabdomyolysis.

Minimum Lethal Exposure

    A) SPECIFIC SUBSTANCE
    1) CASE REPORT: A 45-year-old man developed multi-organ system failure and subsequently died following a massive ingestion of approximately 3 L of mouthwash that contained ethanol 27%, eucalyptol 0.092% (total amount ingested: 2.76 g), menthol 0.042% (total amount ingested: 1.26 g), thymol 0.064% (total amount ingested: 1.92 g), and methyl salicylate 0.060% (total amount ingested: 1.8 g). Although the primary ingredient within the mouthwash is ethanol, the authors believed that the severity and progression of his illness was primarily due to the large ingestion of volatile essential oils present in the mouthwash (total amount of eucalyptol, menthol, and thymol ingested: 5.94 g) (Soo Hoo et al, 2003).
    B) ANIMAL DATA
    1) THUJONE: In rats, parenteral exposure to thujone (volatile oil found in wormwood) concentrations as low as 40 mg/kg have produced seizures, and a dose of 120 mg/kg was fatal (Anon, 1994).

Maximum Tolerated Exposure

    A) CONCENTRATION LEVEL
    1) The concentrations of essential oils in these products may range from 10% to 20%, but are most commonly around 15%. On average, a potentially serious ingestion is in the 1 to 5 g range; this is 6.7 to 33 g of retained product.
    2) In commercial products, it has been estimated that essential oil concentrations may range from 1% to 20% and that doses of 5 to 15 mL may be considered a potentially toxic exposure (Stanton, 1997).
    B) SPECIFIC SUBSTANCE
    1) WORMWOOD OIL: An approximate ingestion of 10 mL of wormwood oil resulted in seizures, acidosis, acute renal failure, and rhabdomyolysis in an adult; recovery was complete (Weisbord et al, 1997).
    C) ANIMAL DATA
    1) In mice studies, it was found that a seasonal variation exists in the composition of sage oil. The winter extract had higher concentrations of camphor, alpha- and beta-thujone, and camphene, while the spring extract was the lowest in toxicity. In comparison, LD50 data for mice after ingestion was 839 mg/kg with the winter extract, and 1200 mg/kg with the spring extract (Farhat et al, 2001).

Toxicity Information

    7.7.1) TOXICITY VALUES
    A) LD50- (ORAL)MOUSE:
    1) 870 mg/kg (Summer)
    2) 955 mg/kg (Fall)
    3) 839 mg/kg (Winter)
    B) ANETHOLE
    1) LD50- (ORAL)RAT:
    a) 2090 mg/kg (Meyer & Meyer, 1959)
    C) ANISE OIL
    1) LD50- (ORAL)RAT:
    a) 2250 mg/kg (Anon, 1990)
    D) CITRAL (major component of LEMON MYRTLE)
    1) LD50- (ORAL)RAT:
    a) 4.96 g/kg with depression followed by death within 4 hour to 4 days (Hayes & Markovic, 2002)
    E) THUJONE (WORMWOOD)
    1) LD50- (SUBCUTANEOUS)RAT:
    a) 134 mg/kg (Lawrence, 1991)

Pharmacologic Mechanism

    A) Many of these products are formulated to take advantage of the rubefacient effects of the essential oils. They may also have marked CNS, spasmolytic, hypotensive, antibacterial, and antitumor activity (Wagner & Wolff, 1977).
    B) LAVENDER OIL - Lavender oil's spasmolytic activity is due primarily to one of its constituents, linalool. In vitro studies of guinea pig ileum showed that the mechanism of action was mediated through an intracellular rise in cAMP, and that contraction inhibition was postsynaptic (Lis-Balchin & Hart, 1999).

Physical Characteristics

    A) Most of the essential oils have characteristic odors eg, oil of turpentine: violets, peppermint, camphor; eucalyptus: camphor-like.

Molecular Weight

    A) Varies

General Bibliography

    1) AMA Department of DrugsAMA Department of Drugs: AMA Evaluations Subscription, American Medical Association, Chicago, IL, 1992.
    2) Agollo MC, Miszputen SJ, & Diament J: Hypericum perforatum-induced hepatotoxicity with possible association with copaiba (Copaifera langsdorffii Desf):case report. Einstein (Sao Paulo) 2014; 12(3):355-357.
    3) Anon: Fd Cos Toxicol 1973; 11:865.
    4) Anon: Patchouli Essential Oil. Madison Avenue Aromatherapy Center. Madison Avenue West, Inc. Denville, NJ, USA. 1997. Available from URL: http:www.madison-avenue.com/aroma/oils/patchouli.htm.
    5) Anon: The Lawrence Review, Facts and Comparisons, St Louis, MO, 1994.
    6) Antman E, Jacob G, & Volpe B: Camphor overdosage: therapeutic considerations. State J Med 1978; 78:896-897.
    7) Barkin ME, Boyd JP, & Cohen S: Acute allergic reaction to eugenol. Oral Surg 1984; 57:441-442.
    8) Brandao FM: Occupational allergy to lavender oil. Contact Dermatitis 1986; 15:249-150.
    9) Brophy GM, Bell R, Claassen J, et al: Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17(1):3-23.
    10) Budavari S: The Merck Index, 12th ed, Merck & Co, Inc, Whitehouse Station, NJ, 1996, pp 117-118.
    11) Burgess JL, Kirk M, Borron SW, et al: Emergency department hazardous materials protocol for contaminated patients. Ann Emerg Med 1999; 34(2):205-212.
    12) Cavanagh HM & Wilkinson JM: Biological activities of lavender essential oil. Phytother Res- PTR 2002; 16(4):301-308.
    13) Chamberlain JM, Altieri MA, & Futterman C: A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Ped Emerg Care 1997; 13:92-94.
    14) Chang YC & Maibach HI: Psuedo flautist's lip: allergic contact cheilitis from geraniol (letter). Cont Derm 1997; 37:39.
    15) Chin RF , Neville BG , Peckham C , et al: Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study. Lancet Neurol 2008; 7(8):696-703.
    16) Choonara IA & Rane A: Therapeutic drug monitoring of anticonvulsants state of the art. Clin Pharmacokinet 1990; 18:318-328.
    17) Craig JO: Poisoning by the volatile oils in childhood. Arch Dis Child 1953; 28:475-483.
    18) Duke JA: Handbook of Medicinal Herbs, CRC Press, Boca Raton, FL, 1985.
    19) Dumitresco SM & Boudene C: Teratological evaluation of Plectranthus fruticosus L'Herit leaf essential oil. Planta Med 1988; 54:296-298.
    20) Farhat GN, Affara NI, & Gali-Muhtasib HU: Seasonal changes in the composition of the essential oil extract of east Mediterranean sage (Salvia libanotica) and its toxicity in mice. Toxicon 2001; 39:1601-1605.
    21) Fisher AA: Contact Dermatitis, 3rd Ed, Lea & Febiger, Philadelphia, PA, 1986.
    22) Fournier G, Pages N, & Dumitresco SM: Contribution to the study of Plectranthus fruticosus leaf essential oil. Planta Med 1986a; 52:486-488.
    23) Fournier G, Pages N, & Paris M: Comparison de la teratogenicite de deux huiles essentielles riches en acetate de sabinyle: Juniperus sabina (Coniferes) et Plectranthus fruticosus (Labiees), CR of the 6th International Symposium on Medicinal Plants and Natural Products', June, Angers, France, 1988.
    24) Fournier G, Pages N, & Paris M: Etude preliminaire de l'effet teratogene de l'huile essentille de plectranthus fruticosus L'Herit, Labiees, CR of the 1st International Congress Plants and Natural Products with Therapeutic Interest, May, Monastir, Tunisia, 1986b.
    25) Giorgi DF, Lobel D, & Morasco R: N-acetylcysteine for pennyroyal oil toxicity (abstract 77), North American Congress of Clinical Toxicology-94, Salt Lake City, UT, 1994.
    26) Grande GA & Dannewitz SR: Symptomatic sassafras oil ingestion. Vet Human Toxicol 1987; 29:447.
    27) Grant WM & Schuman JS: Toxicology of the Eye, 4th ed, Charles C Thomas, Springfield, IL, 1993.
    28) Gurr FW & Scroggie JG: Eucalyptus oil poisoning treated by dialysis and mannitol infusion. Aust Ann Med 1965; 4:238.
    29) Halicioglu O, Astarcioglu G, Yaprak I, et al: Toxicity of Salvia officinalis in a newborn and a child: an alarming report. Pediatr Neurol 2011; 45(4):259-260.
    30) Hansson C, Bergendorff O, & Wallengren J: Contact urticaria caused by carvone in toothpaste. Contact Dermatitis 2011; 65(6):362-364.
    31) Hartnoll G, Moore D, & Douek D: Near fatal ingestion of oil of cloves. Arch Dis Child 1993; 69:392-393.
    32) Hayes AJ & Markovic B: Toxicity of Australian essential oil Backhousia citriodora (Lemon myrtle). Part 1. Antimicrobial activity and in vitro cytotoxicity. Food Chem Toxicol 2002; 40(4):535-543.
    33) Hayes AJ & Markovic B: Toxicity of Australian essential oil Backhousia citriodora (lemon myrtle). Part 2. Absorption and histopathology following application to human skin. Food Chem Toxicol 2003; 41(10):1409-1416.
    34) Hegenbarth MA & American Academy of Pediatrics Committee on Drugs: Preparing for pediatric emergencies: drugs to consider. Pediatrics 2008; 121(2):433-443.
    35) Heng MCY: Local necrosis and interstitial nephritis due to topical methylsalicylate and menthol. Cutis 1987; 39:442-444.
    36) Hvidberg EF & Dam M: Clinical pharmacokinetics of anticonvulsants. Clin Pharmacokinet 1976; 1:161.
    37) Koedam A & Looman A: Effect of pH during distillation on the composition of the volatile oil from Juniperus sabina. Planta Med 1980; (Suppl):22-28.
    38) Landelle C, Francony G, Sam-Lai NF, et al: Poisoning by lavandin extract in a 18-month-old boy. Clin Toxicol (Phila) 2008; 46(4):279-281.
    39) Lis-Balchin M & Hart S: Studies on the mode of action of the essential oil of lavender (Lavandula angustifolia P. Miller). Phytother Res 1999; 13(6):540-542.
    40) Loddenkemper T & Goodkin HP: Treatment of Pediatric Status Epilepticus. Curr Treat Options Neurol 2011; Epub:Epub.
    41) Manno EM: New management strategies in the treatment of status epilepticus. Mayo Clin Proc 2003; 78(4):508-518.
    42) McGeorge BCL & Steele MC: Allergic contact dermatitis of the nipple from Roman chamomile ointment. Contact Dermatitis 1991; 24:139-140.
    43) Meyer FR & Meyer E: Percutane resorption von Atherischen Olen und Ihren Inhaltsstoffen. Arzneim-Forsch 1959; 9:516-519.
    44) Millet Y, Jouglard J, Steinmetz MD, et al: Toxicity of some essential plant oils. Clinical and experimental study. Clin Toxicol 1981; 18(12):1485-1498.
    45) Mullen W, Anderson I, & Oishii S: Accidental pennyroyal oil ingestion in a toddler with the first human serum metabolite detection (abstract 16), North American Congress of Clinical Toxicology-94, Salt Lake City, UT, 1994.
    46) Naradzay J & Barish RA: Approach to ophthalmologic emergencies. Med Clin North Am 2006; 90(2):305-328.
    47) Neher A, Gstottner M, Thaurer M, et al: Influence of essential and fatty oils on ciliary beat frequency of human nasal epithelial cells. Am J Rhinol 2008; 22(2):130-134.
    48) Osol A & Farrar GE: The Dispensatory of the United States of America, 25th ed, JP Lippincott Co, Philadelphia, 1955.
    49) Pages N, Fournier G, & Chamorro G: Teratogenic effects of plectranthus fruticosus essential oil in mice. Phytother Res 1991; 5:94-96.
    50) Pages N, Fournier G, & Chamorro G: Teratological evaluation of Juniperus sabina essential oil in mice. Planta Med 1989; 55:144-146.
    51) Pages N, Salazar M, & Chamorro G: Teratological evaluation of Plactranthus fruticosus L'Herit leaf essential oil. Planta Med 1988; 54:296-298.
    52) Parys BT: Chemical burns resulting from contact with peppermint oil mar; a case report. Burns 1983; 9:374-375.
    53) Peate WF: Work-related eye injuries and illnesses. Am Fam Physician 2007; 75(7):1017-1022.
    54) Perry PA, Dean BS, & Krenzelok EP: Cinnamon abuse by adolescents. Vet Hum Toxicol 1990; 32:162-164.
    55) Pilapil VR: Toxic manifestations of cinnamon oil ingestion in a child. Clin Pediatr 1989; 28:276.
    56) Product Information: diazepam IM, IV injection, diazepam IM, IV injection. Hospira, Inc (per Manufacturer), Lake Forest, IL, 2008.
    57) Product Information: lorazepam IM, IV injection, lorazepam IM, IV injection. Akorn, Inc, Lake Forest, IL, 2008.
    58) Schaller M & Korting HC: Allergic airborne contact dermatitis from essential oils used in aromatherapy. Clin Exp Dermatology 1995; 20:143-145.
    59) Schilcher H: in Baerheim Svendsen & Scheffer JJC (eds): Essential Oils and Aromatic Plants, Dordrecht, The Netherlands, 1985.
    60) Scott R, Besag FMC, & Neville BGR: Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomized trial. Lancet 1999; 353:623-626.
    61) Selvaag E, Eriksen B, & Thune P: Contact allergy due to tea tree oil and cross-sensitization to colophony. Contact Dermatitis 1994; 31:124-125.
    62) Selvaag E, Holm JO, & Thune P: Allergic contact dermatitis in an aroma therapist with multiple sensitizations to essential oils. Contact Dermatitis 1995; 33:354-355.
    63) Sharma R, Bajaj AK, & Singh KG: Sandalwood dermatitis. Int J Dermatology 1987; 26:597-598.
    64) Soo Hoo GW, Hinds RL, Dinovo E, et al: Fatal large-volume mouthwash ingestion in an adult: a review and the possible role of phenolic compound toxicity. J Intensive Care Med 2003; 18:150-155.
    65) Spoerke DG, Vandenberg S, & Smolinske S: Eucalyptus oil: 14 cases of exposure. Vet Hum Toxicol 1989; 31:166-168.
    66) Sreenath TG, Gupta P, Sharma KK, et al: Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: A randomized controlled trial. Eur J Paediatr Neurol 2009; Epub:Epub.
    67) Stafstrom CE: Seizures in a 7-month-old child after exposure to the essential plant oil thuja. Pediatr Neurol 2007; 37(6):446-448.
    68) Stanton GK: Essential oils (letter). J Okla State Med Assoc 1997; 90(8):462.
    69) Temple WA, Smith NA, & Beasley M: Management of oil of citronella poisoning. Clin Toxicol 1991; 29:257-262.
    70) Wagner H & Wolff P: New natural products and plant drugs with pharmacological, biological or therapeutic activity, Springer-Verlag, New York, NY, 1977.
    71) Weisbord SD, Soule JB, & Kimmel PL: Poison on line - Acute renal failure caused by oil of wormwood purchased through the internet. N Engl J Med 1997; 337:825-827.
    72) Wilkinson HF: Childhood ingestion of volatile oils (letter). Med J Australia 1991; 154:430-431.
    73) Woolf A: Essential oil poisoning. Clin Toxicol 1999; 37(6):721-727.
    74) Wyllie JP & Alexander FW: Nasal instillation of 'Olbas Oil' in an infant. Arch Dis Child 1994; 70(4):357-358.